Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GPCR Structure Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: GPCR
Price (delayed)
$26.82
Market cap
$1.54B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.61
Enterprise value
$1.4B
We are a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Our differentiated
Highlights
The equity has surged by 92% year-on-year but it has declined by 4.6% since the previous quarter
GPCR's quick ratio is up by 24% year-on-year but it is down by 6% since the previous quarter
GPCR's debt has soared by 96% QoQ and by 48% YoY
The net income has contracted by 47% YoY and by 17% from the previous quarter
Key stats
What are the main financial stats of GPCR
Market
Valuations
Earnings
Shares outstanding
57.48M
Market cap
$1.54B
Enterprise value
$1.4B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.86
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$182.52M
Net income
-$143.32M
EBIT
-$142.94M
EBITDA
-$140.33M
Free cash flow
-$136.23M
Per share
Balance sheet
Liquidity
EPS
-$2.61
EPS diluted
-$2.61
Free cash flow per share
-$2.38
Book value per share
$14.4
Revenue per share
$0
TBVPS
$15.12
Total assets
$866.55M
Total liabilities
$41.91M
Debt
$7.59M
Equity
$824.64M
Working capital
$813.14M
Debt to equity
0.01
Current ratio
23.29
Quick ratio
22.94
Net debt/EBITDA
1.03
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-15.7%
Return on equity
-16.3%
Return on invested capital
-21.4%
Return on capital employed
-17.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GPCR stock price
How has the Structure Therapeutics stock price performed over time
Intraday
0.83%
1 week
-1.87%
1 month
89.54%
1 year
-31.62%
YTD
-1.11%
QTD
54.94%
Financial performance
How have Structure Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$182.52M
Net income
-$143.32M
Gross margin
N/A
Net margin
N/A
GPCR's operating income has plunged by 59% YoY and by 15% from the previous quarter
The net income has contracted by 47% YoY and by 17% from the previous quarter
Price vs fundamentals
How does GPCR's price correlate with its fundamentals
Growth
What is Structure Therapeutics's growth rate over time
Valuation
What is Structure Therapeutics stock price valuation
P/E
N/A
P/B
1.86
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GPCR's EPS is down by 14% YoY and by 12% QoQ
The equity has surged by 92% year-on-year but it has declined by 4.6% since the previous quarter
GPCR's P/B is 2.1% less than its last 4 quarters average of 1.9
Efficiency
How efficient is Structure Therapeutics business performance
GPCR's return on equity is up by 46% year-on-year but it is down by 3.8% since the previous quarter
GPCR's ROIC is up by 45% YoY
The ROA has increased by 44% year-on-year but it has declined by 4% since the previous quarter
Dividends
What is GPCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GPCR.
Financial health
How did Structure Therapeutics financials performed over time
Structure Therapeutics's total assets has surged by 90% YoY but it has decreased by 4.1% QoQ
Structure Therapeutics's total liabilities has soared by 53% YoY and by 9% from the previous quarter
GPCR's debt is 99% lower than its equity
GPCR's debt has soared by 96% QoQ and by 48% YoY
The equity has surged by 92% year-on-year but it has declined by 4.6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.